Many tropical diseases and infections such as Zika, Dengue, Chagas, Respiratory Syncytial Virus (RSV), and antibiotic-resistant strains of tuberculosis disproportionately affect low and middle-income countries and are under-researched and under-developed. A majority of private investment in drug and vaccine discovery focuses on affluent aging populations globally. Yet, at the same time, basic science research in Latin America and manufacturing in South Asia is advancing rapidly, including on therapeutics and vaccine targets. There is increasing evidence that new models of collaboration can emerge within and between South Asia and Latin America to advance vaccines and therapeutics aligned with the needs of these populations and their comparative R&D advantages. The potential to enhance these collaborations by Harvard faculty who are engaged in understanding incentives and disincentives for innovation will be invaluable toward catalyzing this collaboration across regions and creating new research agendas. During this workshop, we will bring together global scholars, scientists, academic institutions, practitioners, and industry representatives from India, Pakistan, Argentina, Brazil, Chile, and Cuba, who will be joined by experts from Harvard to identify R&D successes and barriers and generate strategies for future South-to-South collaborations. The purpose is to gain an understanding of the state-of-art in country-specific R&D initiatives and of the relevant public policy environment for advancing the agenda on vaccines and therapeutic innovations.
- Ingrid Katz, Harvard Medical School
- Veronica Vargas, Harvard Faculty of Arts & Sciences
- Vijay Kuchroo, Harvard Medical School
- Michael Starnbach, Harvard Medical School